Market News (Page 90) - TendieTensor

Market News Page 90 of 159 • 3,965 articles

Trex Company, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (TREX)

GlobeNewswire Inc. • Kirby Mcinerney Llp

Trex Company, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (TREX)

11/06/2025 08:00 PM • Trex Company reported disappointing Q3 2025 financial results, with net sales 5% below guidance and a significant stock price decline of 31.07%, prompting a potential securities fraud investigation.

AZN - Mentioned as a previous employer of Dr. Smith with no specific context
TREX - Company missed financial guidance, reported declining sales and net income, lowered annual sales growth projection, and experienced a substantial stock price drop following earnings announcement

#securities fraud #financial results #stock decline #inventory strategy

RFN Unleashes the Game-Changing WARRIOR Series at Milan EICMA: Redefining Electric Off-Roading for All Ages

GlobeNewswire Inc. • Zhejiang Apollo Sports Technology Co., Ltd.

RFN Unleashes the Game-Changing WARRIOR Series at Milan EICMA: Redefining Electric Off-Roading for All Ages

11/06/2025 07:40 PM • RFN launches comprehensive WARRIOR electric dirt bike series catering to riders aged 3 to professional adults, featuring advanced safety controls and performance tracking across multiple sub-series.

MRK - Mentioned as a previous employer of Dr. Smith with no specific context
RFIL - Successfully launching a comprehensive electric dirt bike series targeting multiple age groups and skill levels, showing strong product development and market understanding

#electric dirt bikes #off-road vehicles #electric mobility #youth sports technology

Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products

GlobeNewswire Inc. • Not Specified

Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products

11/06/2025 07:09 PM • Kelyniam Global has renewed its licensing agreement with Finceramica for three years, gaining exclusive access to advanced biomaterials like SINTlife, a fully resorbable synthetic graft expected to receive FDA clearance within two years.

SKYE - Mentioned as a board membership with no specific performance details
KLYG - Company is expanding its product portfolio, securing exclusive distribution rights, and positioning itself for growth in high-potential markets

#licensing agreement #biomaterials #cranial implants #regenerative medicine #FDA clearance

DIVIDEND DECLARATION - Wheaton Precious Metals Announces Quarterly Dividend

Benzinga • Prnewswire

DIVIDEND DECLARATION - Wheaton Precious Metals Announces Quarterly Dividend

11/06/2025 06:44 PM • Wheaton Precious Metals Corp. declared its fourth quarterly cash dividend of US$0.165 per common share for 2025, representing a 6.5% increase from the previous year. The dividend will be paid on December 4, 2025, to shareholders of record as of November 20, 2025.

WPM - The company increased its quarterly dividend by 6.5%, signaling financial strength and commitment to shareholder returns. Additionally, they are maintaining their dividend reinvestment plan and changing transfer agents, indicating proactive management.

#dividend #quarterly dividend #precious metals #investor relations

Shamis & Gentile, P.A. Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of agilon health, inc. – AGL

GlobeNewswire Inc. • David Abel

Shamis & Gentile, P.A. Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of agilon health, inc. – AGL

11/06/2025 06:44 PM • Law firm investigating potential fiduciary duty breaches by agilon health directors and executives after the company lowered 2023 profit forecasts, citing higher medical costs and leading to a significant stock price drop.

CNTX - Mentioned as a board membership with no specific performance details
AGL - Stock dropped 28.6% after lowering profit forecasts, facing allegations of misleading investors about medical costs, utilization trends, and financial risk disclosures. A securities class action lawsuit has been filed against the company and its executives.

#securities fraud #fiduciary duties #medical costs #financial guidance #stock price

CarMax, Inc. (KMX) Tumbles Again Amid CEO Termination, Preliminary Q3 Results; Securities Class Action Pending – Hagens Berman

GlobeNewswire Inc. • Hagens Berman

CarMax, Inc. (KMX) Tumbles Again Amid CEO Termination, Preliminary Q3 Results; Securities Class Action Pending – Hagens Berman

11/06/2025 06:40 PM • CarMax announced CEO Bill Nash's termination and released disappointing Q3 preliminary financial results, with a projected comparable store unit decrease of 8-12% and lower-than-expected earnings. A securities class action has been filed alleging misleading investor communications.

KMX - Stock price tumbled 23%, CEO fired, preliminary Q3 results significantly below analyst expectations, facing potential securities class action lawsuit, and showing signs of market share loss and margin pressure

#CarMax #CEO termination #financial results #securities class action #investor losses

NGG Investor News: If You Have Suffered Losses in National Grid plc (NYSE: NGG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

NGG Investor News: If You Have Suffered Losses in National Grid plc (NYSE: NGG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/06/2025 06:33 PM • A potential securities class action lawsuit has been initiated against National Grid following a Reuters report about a Heathrow airport fire caused by power grid maintenance failures, which led to a 5% drop in the company's stock price.

GEV - Established blue chip company with diverse energy expertise, potential strategic connections with OpenAI, and a more stable investment profile
NGG - The article highlights a critical report suggesting systemic maintenance failures that caused a significant airport disruption, with an official report noting an unaddressed issue from seven years prior, leading to potential legal action and stock price decline

#securities lawsuit #power grid #Heathrow airport #investor losses

Consumer Expert Andrea Woroch Shares Target’s Early Black Friday Savings Tips on YourUpdateTV

GlobeNewswire Inc. • Andrea Woroch

Consumer Expert Andrea Woroch Shares Target’s Early Black Friday Savings Tips on YourUpdateTV

11/06/2025 06:31 PM • Target launches a three-day Early Black Friday Sale from November 6-8, offering discounts up to 50% on apparel, toys, home decor, tech, and kitchen essentials from popular brands like LEGO, Barbie, Beats, and Ninja.

TGT - Offering extensive discounts across multiple product categories, providing consumer-friendly shopping options and early access to holiday deals

#holiday shopping #Black Friday #Target #discounts #consumer savings

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

GlobeNewswire Inc. • Eledon Pharmaceuticals

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

11/06/2025 06:30 PM • Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart, a potential new immunosuppression treatment for kidney transplant patients, showing promising safety and efficacy with reduced side effects compared to tacrolimus.

ELDN - Company presented promising clinical trial results demonstrating potential breakthrough in kidney transplant immunosuppression, with plans to advance to Phase 3 development and strong safety profile for tegoprubart

#kidney transplant #immunosuppression #tegoprubart #clinical trial #Phase 2

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

GlobeNewswire Inc. • Akebia Therapeutics

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

11/06/2025 06:30 PM • Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.

PM - Successfully transitioning to smoke-free products, strong growth in nicotine pouches and heated tobacco, recent significant dividend increase of 8.9%, and promising trajectory in replacing traditional cigarette revenues
AKBA - Presented favorable clinical trial data showing statistically significant benefits of their drug vadadustat in treating anemia in dialysis patients, potentially improving treatment standards

#vadadustat #dialysis #chronic kidney disease #anemia #clinical trial

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

GlobeNewswire Inc. • Scott+Scott Attorneys At Law Llp

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

11/06/2025 06:28 PM • Alvotech received a complete response letter from the FDA for its biosimilar candidate AVT05, indicating manufacturing facility deficiencies that must be resolved before approval. The stock price dropped 34% following the announcement.

ALVO - FDA issued a complete response letter requiring resolution of manufacturing facility deficiencies, which caused a significant 34% stock price drop and signals potential delays in product approval

#FDA #biosimilar #Simponi #manufacturing #regulatory

The Motley Fool • Eric Volkman

Why Costco Stock Slipped Today

11/06/2025 06:13 PM • Costco reported October sales of $21.75 billion, a 9% year-over-year increase, with comparable sales rising 6.6%. Despite solid performance, an analyst reduced the price target, causing a mild stock decline.

COST - Strong sales growth (9% YoY) was offset by a price target reduction from J.P. Morgan analyst due to potential business impact from government shutdown

#retail #monthly sales #stock performance #price target

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire Inc. • Medicinova, Inc.

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

11/06/2025 06:00 PM • MediciNova received the Contract Research and Development Innovation Award for its innovative work on MN-166, a small molecule drug candidate targeting neurological diseases like ALS, demonstrating promising therapeutic potential.

MNOV - Company received an innovation award, advancing promising drug candidate for neurological diseases, showing strong research and development progress

#biotechnology #neurodegenerative diseases #ALS #drug development #innovation award

Orange: Orange successfully completes a bond issuance in 5 tranches for a total amount of 5 billion euros

GlobeNewswire Inc. • Tom Wright, Fatima Rahil

Orange: Orange successfully completes a bond issuance in 5 tranches for a total amount of 5 billion euros

11/06/2025 05:59 PM • Orange has completed a €5 billion bond issuance across 5 tranches with varying maturities and coupon rates, demonstrating strong market confidence in its strategic plan and potential MasOrange acquisition.

EVGOW - The article is a standard financial results announcement without strong positive or negative indicators, presenting routine business communication about an upcoming earnings report
ORANY - Successfully raised €5 billion through bond issuance with high investor demand (order book exceeded €20 billion), indicating strong market confidence in the company's strategic direction

#bond issuance #telecommunications #financing #MasOrange #strategic plan

Orange: Orange réalise avec succès une émission obligataire en 5 tranches pour un montant total de 5 milliards d’euros

GlobeNewswire Inc. • Orange Press Team

Orange: Orange réalise avec succès une émission obligataire en 5 tranches pour un montant total de 5 milliards d’euros

11/06/2025 05:59 PM • Orange successfully issued a 5 billion euro bond across 5 tranches with varying maturities and coupon rates, demonstrating strong market confidence in its strategic plan and potential MasOrange acquisition.

ORANY - Successfully raised 5 billion euros with strong market demand (over 20 billion euro order book), indicating investor confidence in the company's strategic direction and financial health

#bond issuance #telecommunications #financing #MasOrange #strategic expansion

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD)

GlobeNewswire Inc. • Brodsky & Smith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD)

11/06/2025 05:50 PM • Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during merger and acquisition processes, focusing on whether shareholders are receiving fair value.

QRVO - Potential breach of fiduciary duties in Skyworks acquisition, with concerns about fair value for shareholders

#mergers #acquisitions #shareholder investigations #fiduciary duties

Targa Resources Corp. Prices $1.75 Billion Offering of Senior Notes

GlobeNewswire Inc. • Targa Resources Corp.

Targa Resources Corp. Prices $1.75 Billion Offering of Senior Notes

11/06/2025 05:48 PM • Targa Resources Corp. announced a public offering of $750 million in 4.350% Senior Notes due 2029 and $1.0 billion in 5.400% Senior Notes due 2036, with proceeds to be used for debt redemption and general corporate purposes.

NTRBW - Company received constructive FDA feedback, moving forward with development of innovative abuse deterrent technology with potential market value of $80-200 million
TRGP - The company is executing a standard debt refinancing strategy, issuing new notes at lower interest rates to replace existing higher-interest debt, which suggests prudent financial management without significant positive or negative implications

#senior notes #public offering #debt refinancing #midstream services

Xanadu Advances to Stage B of DARPA’s Quantum Benchmarking Initiative, Securing up to $15 Million in Funding

GlobeNewswire Inc. • Xanadu Quantum Technologies Inc.

Xanadu Advances to Stage B of DARPA’s Quantum Benchmarking Initiative, Securing up to $15 Million in Funding

11/06/2025 05:45 PM • Xanadu Quantum Technologies has advanced to Stage B of DARPA's Quantum Benchmarking Initiative, securing up to $15 million in funding and demonstrating progress towards developing a utility-scale quantum computer by 2029.

CHAC - Involved in a potential business combination with Xanadu, providing potential funding but no specific technological achievements mentioned

#quantum computing #photonic quantum computing #DARPA #quantum benchmarking #technology development

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - IMXI, FSFG, FITB, and CMA

Benzinga • Juan Monteverde

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - IMXI, FSFG, FITB, and CMA

11/06/2025 05:30 PM • Law firm Monteverde & Associates is investigating potential merger-related shareholder actions for four companies involving potential mergers and acquisitions.

CMG - Mentioned as a pivotal player in the market's growth trajectory with potential for expansion
IMXI - Being sold to Western Union for $16.00 per share, with shareholder vote scheduled

#merger #acquisition #shareholder #investigation #class action

Robinhood's Growth 'Shows No Signs Of Slowing Down'

Benzinga • Erica Kollmann

Robinhood's Growth 'Shows No Signs Of Slowing Down'

11/06/2025 05:20 PM • Robinhood Markets reported record Q3 revenue of $1.27 billion, representing 100% year-over-year growth. Analysts are impressed by the company's prediction markets business and crypto volume rebound, with multiple firms raising price targets.

DRI - Identified as a significant contributor to the market's development and growth
HOOD - Strong Q3 performance with 100% revenue growth, successful expansion into prediction markets, 40.6% increase in crypto trading volumes, and multiple analyst price target upgrades

#fintech #brokerage #earnings #prediction markets #crypto trading

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

Benzinga • Piero Cingari

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

11/06/2025 05:12 PM • President Trump announced a major pricing deal with Eli Lilly and Novo Nordisk to make weight-loss drugs more affordable, with Medicare and Medicaid coverage starting in April 2026 and monthly out-of-pocket costs reduced to $50-$350.

HELFY - Mentioned as expanding into online grocery space, indicating strategic market positioning
LLY - Stock up 20% year-to-date, strong demand for Zepbound, investor optimism about weight-loss and diabetes treatment pipeline

#obesity drugs #weight loss #healthcare #drug pricing #Medicare #Medicaid

Why Resideo Technologies Stock Plummeted by Almost 24% on Thursday

The Motley Fool • Eric Volkman

Why Resideo Technologies Stock Plummeted by Almost 24% on Thursday

11/06/2025 05:06 PM • Resideo Technologies experienced a significant stock drop after reporting Q3 earnings that narrowly missed analyst expectations, with guidance for the year falling short of market predictions.

REZI - Stock dropped 24% due to missed revenue guidance, despite beating earnings expectations and showing organic growth. The company's full-year forecast was lower than analyst estimates, causing investor concern.

#earnings #stock market #technology #guidance #quarterly report

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

GlobeNewswire Inc. • Cytek Biosciences

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

11/06/2025 05:00 PM • Cytek Biosciences' Muse Micro cell analyzer won the 2025 BioTech Breakthrough Award for Drug Discovery Solution of the Year, highlighting its innovative approach to making cell analysis more accessible and cost-effective for laboratories.

RNA - Acquired by Novartis for $12 billion, indicating strategic value in neuroscience and rare disease pipeline
CTKB - Company received a prestigious industry award, showcased technological innovation, and demonstrated commitment to making advanced scientific tools more accessible and affordable

#cell analysis #flow cytometry #drug discovery #biotechnology #innovation

Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm

GlobeNewswire Inc. • Lowey Dannenberg P.C.

Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm

11/06/2025 05:00 PM • Lowey Dannenberg filed a class action lawsuit against Baxter International for alleged securities law violations related to Novum LVP medical device defects that potentially exposed patients to serious risks.

BAX - Lawsuit alleges systematic product defects in Novum LVP pumps causing potential patient harm, misleading investor statements, and stock price decline

#securities lawsuit #medical device #investor claims #product defects

Opendoor Announces Shareholder‑First Dividend of Tradable Warrants Aligning Shareholders and Management

Benzinga • Globe Newswire

Opendoor Announces Shareholder‑First Dividend of Tradable Warrants Aligning Shareholders and Management

11/06/2025 04:36 PM • Opendoor Technologies is distributing tradable warrants to shareholders as a way to align management interests with investor value, offering three series of warrants at different exercise prices, with no upfront cost to shareholders.

OPEN - The company is proactively creating a shareholder-friendly mechanism by distributing free warrants that provide potential upside, demonstrating transparency and commitment to investor interests. CEO Kaz Nejatian explicitly states the goal is to rebuild trust and provide shareholders with performance-based opportunities.

#warrants #shareholder alignment #dividend #stock distribution